-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on Cellebrite DI, Lowers Price Target to $15

Benzinga·11/13/2026 20:09:23
Listen to the news
JP Morgan analyst Brian Essex maintains Cellebrite DI (NASDAQ:CLBT) with a Overweight and lowers the price target from $16 to $15.